NCT07449234Terminated
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
A Non-interventional, Multi-centric, Single Country Observational Study to Assess the Safety and Effectiveness of Guselkumab After Ustekinumab (Originator or Biosimilar) in Moderate to Severe Psoriasis Patients in Clinical Routine
Source: ClinicalTrials.gov · Last updated 27 Jul 2026
Brief summary (registry, in English)
The purpose of this study is to assess the effectiveness and safety of guselkumab following a switch from ustekinumab or an ustekinumab biosimilar in participants with moderate to severe psoriasis, a chronic inflammatory skin disease characterized by erythematous, scaly plaques that may be associated with pain and pruritus, in routine clinical practice.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 9 (actual)
- First submitted
- 27 Feb 2026
- Start date
- 9 Feb 2026
- Primary completion date
- 29 Jun 2026
- Lead sponsor
- Janssen-Cilag Ltd.
- Diseases
- Psoriasis
- NCT number
- NCT07449234
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindication or hypersensitivity to Guselkumab or any ingredient in the injection solution/liquid
Other
- Pregnancy or breastfeeding
- Currently enrolled in an interventional study
- Currently enrolled in an observational study sponsored or managed by a Janssen company
Who the study is looking for
- Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment
- Participants who are currently treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab
- Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab
- Participants must understand and be willing and able to answer patient-reported outcomes (PROs)
- Must sign an informed consent form (ICF) allowing data collection and source data verification in accordance with local requirements
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lkh-Univ. Klinikum Graz Coordinator of this site? Confirm its status | Graz | Austria | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.